Margetuximab
Margenza (margetuximab) is an antibody pharmaceutical. Margetuximab was first approved as Margenza on 2020-12-16. The pharmaceutical is active against receptor tyrosine-protein kinase erbB-2.
Trade Name | Margenza |
---|---|
Common Name | Margetuximab |
Indication | |
Drug Class | Monoclonal antibodies: chimeric, tumors as target |
